{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:45:25Z","timestamp":1779165925091,"version":"3.51.4"},"reference-count":39,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2041320","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T08:37:09Z","timestamp":1645087029000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada"],"prefix":"10.1080","volume":"25","author":[{"given":"Denise","family":"Zou","sequence":"first","affiliation":[{"name":"Modeling and Simulations, Evidera, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lee","sequence":"additional","affiliation":[{"name":"Modeling and Simulations, Evidera, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuraag","family":"Kansal","sequence":"additional","affiliation":[{"name":"Modeling and Simulations, Evidera, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenkang","family":"Ma","sequence":"additional","affiliation":[{"name":"Modeling and Simulations, Evidera, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mack","family":"Harris","sequence":"additional","affiliation":[{"name":"Modeling and Simulations, Evidera, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Seagen Inc., Bothell, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keenan","family":"Fenton","sequence":"additional","affiliation":[{"name":"Biostatistics, Seagen Inc., Bothell, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina S.","family":"Yu","sequence":"additional","affiliation":[{"name":"Health Economics Outcomes Research, Seagen Inc., Bothell, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.836"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191292"},{"key":"e_1_3_4_7_1","first-page":"15","article-title":"Filling the void of Canadian T-cell lymphoma epidemiology: data from the Canadian Institute for Health Information discharge abstract database","volume":"75","author":"Mahe ER","year":"2015","unstructured":"Mahe ER, Pugh T, Stockley T, et\u00a0al. Filling the void of Canadian T-cell lymphoma epidemiology: data from the Canadian Institute for Health Information discharge abstract database. Am Assoc Cancer Res. 2015;75:15.","journal-title":"Am Assoc Cancer Res"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv201"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-516245"},{"key":"e_1_3_4_10_1","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation (Adcetris). 2018."},{"key":"e_1_3_4_11_1","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation (Adcetris) for HL 2013. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-adcetrishl-fn-rec.pdf"},{"key":"e_1_3_4_12_1","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation (Adcetris) for sALCL 2013. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-adcetris-salcl-fn-rec.pdf"},{"key":"e_1_3_4_13_1","unstructured":"L\u2019Institut National d'Excellence En Sant\u00e9 Et En Services Sociaux. ADCETRISMC \u2013 lymphome anaplasique \u00e0 grandes cellules syst\u00e9mique 2014. Available from: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Fevrier_2014\/adcetris_lagcs_2014_02_CAV.pdf"},{"key":"e_1_3_4_14_1","unstructured":"L\u2019Institut National d'Excellence En Sant\u00e9 Et En Services Sociaux. ADCETRISMC \u2013 lymphome de Hodgkin 2014. Available from: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Juin_2014\/Adcetris__LH_2014_06_CAV.pdf"},{"key":"e_1_3_4_15_1","unstructured":"L\u2019Institut National d'Excellence En Sant\u00e9 Et En Services Sociaux. ADCETRISMC \u2013 lymphome de Hodgkin 2018. Available from: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Fevrier_2018\/Adcetris_2018_02.pdf"},{"key":"e_1_3_4_16_1","unstructured":"Adcetris [Product Monograph]. Bothell WA: Seagen Inc.; 2019."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8552"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"e_1_3_4_19_1","first-page":"S0923-7534(21)0","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"2021","author":"Horwitz S","year":"2021","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et\u00a0al. The ECHELON-2 trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2021;2021:S0923-7534(21)04875-4.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","unstructured":"Horowitz SM O\u2019Connor OA Pro B et\u00a0al. editors. The ECHELON-2 trial: 5-year results of a randomized double-blind phase 3 study of brentuximab vedotin and CHP (A\u2009+\u2009CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma. 62nd ASH Annual Meeting and Exposition; 2020 December 5\u20138; Virtual.","DOI":"10.1182\/blood-2021-145124"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.7_suppl.18"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.42400"},{"key":"e_1_3_4_23_1","volume-title":"Guidelines for the economic evaluation of health technologies: Canada","author":"Canadian Agency for Drugs and Technologies in Health (CADTH)","year":"2017","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. 4th edition. 2017.","edition":"4"},{"key":"e_1_3_4_24_1","unstructured":"Seagen Inc. Document on file \u2013 Cost-effectiveness of brentuximab vedotin for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma peripheral T-cell lymphomas not otherwise specified or angioimmunoblastic T-cell lymphoma whose tumors express CD30: Canadian pCODR technical report. 2019."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861"},{"key":"e_1_3_4_28_1","unstructured":"EuroQol Research Foundation. EQ-5D-3L User Guide. 2018. [June 8 2021]."},{"key":"e_1_3_4_29_1","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation for brentuximab vedotin (Adcetris) for peripheral T-cell lymphoma 2020. Available from: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10199BrentuximabVedotinPTCL_FnRec_approved_Post04Jun2020_final.pdf"},{"key":"e_1_3_4_30_1","unstructured":"NEUPOGEN (filgrastim) [package insert]. U.S. Food and Drug Administration website 2015 [cited 2021 Mar 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103353s5184lbl.pdf"},{"key":"e_1_3_4_31_1","unstructured":"ADCETRIS (brentuximab vedotin) [package insert] U.S. Food and Drug Administration website 2014. [cited 2021 Mar 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125388_s056s078lbl.pdf"},{"key":"e_1_3_4_32_1","unstructured":"Ontario Ministry of Health and Long-Term Care (MOHLTC). Schedule of benefits. Physician services. [cited 2019 Mar 20]. Available from: https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/"},{"key":"e_1_3_4_33_1","unstructured":"Ontario Ministry of Health and Long-Term Care (MOHLTC). Interprovincial billing rates for designated high cost transplants effective for discharges on or after April 1 2018. 2018 [cited 2019 Mar 20]. Available from: https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/bulletins\/na_84\/high_cost_procedures.pdf"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/082585971102700203"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4565"},{"key":"e_1_3_4_36_1","unstructured":"Ontario Case Costing Initiative. Cost analysis tool \u2013 Acute inpatient and ambulatory 2016\/2017 statistics by most responsible diagnosis [March] 2019."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"e_1_3_4_38_1","unstructured":"Woods B Sideris E Palmer N et\u00a0al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2017. [January 3 2019]."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00738.x"},{"key":"e_1_3_4_40_1","unstructured":"Ontario Case Costing Initiative. Cost analysis tool \u2013 Acute inpatient and ambulatory 2016\/2017 statistics by most responsible diagnosis [March 2019]."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2041320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:05:03Z","timestamp":1729163103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2041320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2041320"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2041320","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}